And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, once again, rather modest. We plan to catch up on our reading, indulge ourselves with a few naps, hang with one or more short people, and take in another installment in our Let’s-see-them-before-they-die concert series. And what about you? This is a good time to sample some of those moving pictures that recently won awards. You could curl up with a good e-book or make time for someone special. Or start placing bets on the next big election. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.

Pfizer (PFE) received a request for documents as part of a U.S. investigation into quality-control problems at a subsidiary that makes the EpiPen device for Mylan (MYL), according to a regulatory filing. In 2017, the Meridian Medical Technologies unit was cited by regulators for a failure to investigate “serious” problems associated with an unspecified number of patient deaths. Within days of an FDA inspection, Mylan began recalling EpiPen devices from the U.S., Europe, Asia, and North and South America due to a product defect that, at the time, Mylan claimed “occurs rarely.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy